PO.CL01.13 · 临床研究
NMIBC进展的微环境驱动因素的空间转录组学解析
Spatial transcriptomic dissection of microenvironmental drivers of NMIBC progression
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:高级别非肌层浸润性膀胱癌(NMIBC)是一种侵袭性恶性肿瘤,其特点是进展为肌层浸润性膀胱癌(MIBC)的比率很高。一旦发生肌层浸润,该疾病便与显著更差的总生存期相关。因此,迫切需要识别治疗靶点和进展生物标志物的新策略。我们利用空间转录组学阐明了驱动NMIBC进展的肿瘤微环境状态和细胞间相互作用。我们假设进展性NMIBC由独特的分子和结构组成所定义,这些组成趋同于一种MIBC样表型。
方法:我们使用经尿道切除标本构建了组织微阵列,来自18例在5年内进展为MIBC的高级别NMIBC患者和27例风险匹配的非进展者,以及52例MIBC膀胱切除标本。随后,我们使用一个5,000基因组合并额外100个聚焦于基质和免疫信号传导的基因,进行了Xenium原位表达分析。数据分析采用单细胞变分推断,结合基于Leiden聚类的细胞分型、自定义邻域(“生态位”)评估,以及计算工作流程,以刻画跨进展状态和疾病状态的细胞相互作用、转录程序和配体-受体信号传导。
结果:我们生成了一个跨越NMIBC和MIBC组织、涵盖超过400万个细胞的单细胞分辨率空间转录组图谱。初步分析揭示了肿瘤内在转录程序和微环境组成方面均存在显著的患者内和患者间异质性。非进展者肿瘤表现出增强的免疫激活特征以及细胞毒性CD8+ T细胞的富集,而进展者则表现出肿瘤mTOR信号传导和其他致癌通路的富集。正在进行的工作旨在定义区分进展性与非进展性疾病的空间生态位和细胞相互作用网络,并评估它们与MIBC样结构的一致性。
结论:本研究建立了首个直接比较NMIBC进展者与非进展者的单细胞空间转录组分析,为定义进展至浸润的微环境轨迹提供了框架。通过利用高分辨率空间转录组学识别候选生物标志物和潜在的浸润驱动因素,这项工作可为早期风险分层以及旨在预防向MIBC转变的微环境靶向疗法提供参考。
查看英文原文 English abstract
Background: High‐grade non-muscle invasive bladder cancer (NMIBC) is an aggressive malignancy characterized by a high rate of progression to muscle-invasive bladder cancer (MIBC). Once muscle-invasive, the disease is associated with significantly worse overall survival. Thus, novel strategies for identifying therapeutic targets and biomarkers of progression are urgently needed. We utilized spatial transcriptomics to elucidate the tumor microenvironment states and cellular interactions that underlie progressive NMIBC. We hypothesized that progressive NMIBC is defined by distinct molecular and architectural compositions that converge on an MIBC-like phenotype.
Methods: We constructed tissue microarrays using transurethral resection specimens from 18 high-grade NMIBC patients who progressed to MIBC within 5 years and 27 risk-matched non-progressors, along with 52 MIBC cystectomy specimens. We then performed Xenium in situ expression analysis using a 5,000-gene panel with an additional 100 genes focused on stromal and immune signaling. Data were analyzed using single-cell variational inference with Leiden clustering-based cell typing, custom neighborhood (“niche”) evaluation, and computational workflows to characterize cellular interactions, transcriptional programs, and ligand-receptor signaling across progressor status and disease states.
Results: We generated a single-cell-resolution spatial transcriptomic atlas of over 4 million cells spanning NMIBC and MIBC tissues. Preliminary analysis revealed substantial intra- and inter-patient heterogeneity in both tumor-intrinsic transcriptional programs and microenvironment composition. Non-progressor tumors demonstrated increased immune activation signatures and enrichment of cytotoxic CD8+ T cells, while progressors showed enrichment of tumoral mTOR signaling and other oncogenic pathways. Ongoing work aims to define spatial niches and cellular interaction networks that differentiate progressive versus non-progressive disease and evaluate their alignment with MIBC-like architecture.
Conclusions: This study establishes the first single-cell spatial transcriptomic analysis directly comparing NMIBC progressors and non-progressors, providing a framework to define microenvironmental trajectories underlying progression to invasion. By leveraging high-resolution spatial transcriptomics to identify candidate biomarkers and potential drivers of invasion, this work may inform early risk stratification and microenvironment-targeted therapeutics aimed at preventing transition to MIBC.
利益披露 Disclosure
J. Alltucker,
Scorpion Therapeutics Stock, Stock Option.
Y. Shen, None..
S. Choi, None..
P. Nedumaran, None..
A. Martinez, None..
H. Ye, None..
D. Theodorescu, None.
S. Knott,
Faeth Therapuetics Stock, Other, Founder.